• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Tislelizumab plus chemotherapy improves outcomes for advanced squamous non small cell lung cancer over chemotherapy alone

byConstance Wu
April 13, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Tislelizumab, a monoclonal antibody and PD1/L1 inhibitor, when combined with chemotherapy, showed significantly prolonged progression free survival and higher objective response rate, compared with chemotherapy alone.

Evidence Rating Level: 1 (Excellent)

Squamous non-small-cell lung cancers (sq-NSCLCs) are often diagnosed at a later stage, leading to poor prognosis and difficult disease management. However, there has been promise shown when combining chemotherapy with monoclonal antibody treatments that block programmed cell death receptor 1 and its ligand (PD-1/L1 inhibitors). The sole approved treatment for advanced sq-NSCLC is a PD-1/L1 inhibitor (pembrolizumab) and standard chemo. This led to research into the potential of tislelizumab, a monoclonal antibody of the same class. Early trials showed that combining tislelizumab with platinum-based therapy was well tolerated, demonstrated antitumour activity, and had an 80% or 67% objective response rate, depending on the chemo regimen used. This current study was a phase 3 trial examining the efficacy and safety of tislelizumab plus chemotherapy for advanced sq-NSCLC.  The study population consisted of 360 patients (median [range] age of 62 [34-74] years; 91.7% male) with stage IIIb or IV sq-NSCLC. They were randomized roughly equally into 3 arms: Arm A consisted of tislelizumab plus paclitaxel and carboplatin, Arm B consisted of tislelizumab plus nab-paclitaxel and carboplatin, and Arm C consisted of paclitaxel and carboplatin (no tislelizumab). These regimens were administered intravenously every 3 weeks, and the outcomes investigated were progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR), all assessed by an independent review committee. After a median follow-up of 8.6 months, the PFS was 7.6 months in Arms A and B, compared to 5.5 months in Arm C (hazard ratio 0.524, 95% CI 0.370-0.742, p < 0.001 for Arm A vs C; HR 0.478, 95% CI 0.336-0.679, p < 0.001 for Arm B vs C). The arms with tislelizumab experienced higher ORRs and longer DOR, which were 72.5% and 8.2 months in Arm A, 74.8% and 8.6 months in Arm B, and 49.% and 4.2 months in Arm C. In terms of adverse events, discontinuation due to treatment was found in 12.5% of Arm A, 29.7% of Arm B, and 15.4% of Arm C. The adverse events found were consistent with known adverse events of chemotherapy. Overall, this study demonstrated that tislelizumab combined with chemotherapy significantly reduced the risk for progression or death in advanced squamous non-small-cell lung cancer patients.

Click to read the study in JAMA Oncology

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

Tags: CoronavirusSARS-CoV-2
Previous Post

Time-limited trials may decrease the length of stay of critically ill patients in the intensive care unit

Next Post

Clinical outcomes of infants breastfeeding from mothers with COVID-19

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19
StudyGraphics

#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19

August 12, 2024
Next Post
Ear infections decreasing in infants

Clinical outcomes of infants breastfeeding from mothers with COVID-19

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Polypill plus aspirin treatment decreases cardiovascular event incidence

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

Targeted intervention improved infant bronchiolitis treatment by deimplementing ineffective management practices

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk
  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.